CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-20 | Humes Jennifer Chief Accounting Officer | Shares withheld for taxes | −14,526 | $27.70 | $402K | 97,729 |
| 2026-03-17 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,847,546 |
| 2026-03-17 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $28.24 | $5.6M | 1,647,546 |
| 2026-03-17 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,844,834 | ||
| 2026-03-16 | Epperly Melissa B, Director | Sale | −41,861 | $28.68 | $1.2M | 15,804 |
| 2026-02-23 | Torti Frank President and Vant Chair | Option exercise 10b5-1 | +587,390 | $3.85 | $2.3M | 14,323,937 |
| 2026-02-23 | Torti Frank President and Vant Chair | Sale 10b5-1 | −587,390 | $27.51 | $16.2M | 13,736,547 |
| 2026-02-23 | Torti Frank President and Vant Chair | Option exercise · Stock Option (Right to Buy) 10b5-1 | −587,390 | 3,026,184 | ||
| 2026-02-20 | Pulik Richard CFO | Shares withheld for taxes | −1,000 | $27.15 | $27K | 238,413 |
| 2026-02-20 | Venker Eric President & Immunovant CEO | Shares withheld for taxes | −7,051 | $27.15 | $191K | 1,647,546 |
| 2026-02-20 | Torti Frank President and Vant Chair | Option exercise 10b5-1 | +1,012,610 | $3.85 | $3.9M | 14,749,157 |
| 2026-02-20 | Torti Frank President and Vant Chair | Sale 10b5-1 | −1,012,610 | $27.15 | $27.5M | 13,736,547 |
| 2026-02-20 | Torti Frank President and Vant Chair | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,012,610 | 3,613,574 | ||
| 2026-02-19 | Torti Frank President and Vant Chair | Option exercise 10b5-1 | +1,400,000 | $3.85 | $5.4M | 15,136,547 |
| 2026-02-19 | Torti Frank President and Vant Chair | Sale 10b5-1 | −1,400,000 | $27.42 | $38.4M | 13,736,547 |
| 2026-02-19 | Torti Frank President and Vant Chair | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,400,000 | 4,626,184 | ||
| 2026-02-13 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,854,597 |
| 2026-02-13 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $26.49 | $5.3M | 1,654,597 |
| 2026-02-13 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 5,044,834 | ||
| 2026-02-13 | MANCHESTER KEITH S Director | Sale | −150,784 | $26.49 | $4.0M | 15,352,329 |
Page 10 of 29 · 570 trades